News Indivior's once-monthly schizophrenia injection gets US gree... Regulators authorities in the US have approved Indivior’s long-acting injectable treatment for adults with schizophrenia.
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.